US Biomax - Prostate Cancer Tissue Array, Including TNM, Clinical Stage And Pathology Grade, 80 Cases/80 Cores, Replacing PR803

Prostate Sub-types (59)

Paraffin Embedded Tissue Array Types [view all]

Human

PR803a

Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 80 cases/80 cores, replacing PR803

Unstained: $255.00

H&E (PR803as*): $255.00

Microarray Panel:	Prostate adenocarcinoma tissue microarray, containing 71 cases of prostate adenocarcinoma, 2 prostate leiomyosarcoma, 1 prostate hyperplasia, plus 6 normal prostate tissue, single core per case
Cores:	80
Cases:	80
Layout:	10 cols × 8 rows
Core Diameter:	1.5 mm
Thickness:	5 µm
Quality Control:	Anti-Actin confirmed
Applications:	Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:	Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

Unstained: unstained paraffin tissue microarray slide.
Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

Slide Label: US Biomax, Inc. Tissue Array

	1	2	3	4	5	6	7	8	9	10
A
B
C
D
E
F
G
H

Legend:

Pro - Prostate

- Hyperplasia, - Malignant tumor, - Malignant tumor (stage I), - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IIIB), - Malignant tumor (stage IV), - NAT, - Normal tissue

Specification Sheet

Pos	No.	Sex	Age	Organ	Pathology diagnosis	Grade	Stage	Gleason Grade	Gleason Score	TNM	Type †
A1	1	M	60	Prostate	Adenocarcinoma	1	IV	2	2+2	T4N1M1	Malignant
A2	2	M	75	Prostate	Adenocarcinoma	1	IV	2	2+2	T2N0M1c	Malignant
A3	3	M	60	Prostate	Adenocarcinoma	3	III	4	5+4	T3aN0M0	Malignant
A4	4	M	71	Prostate	Adenocarcinoma	2	II	3	3+3	T2N0M0	Malignant
A5	5	M	66	Prostate	Adenocarcinoma	2	IV	3	3+3	T3N1M1	Malignant
A6	6	M	67	Prostate	Adenocarcinoma	2	IV	3	2+3	T2N0M1	Malignant
A7	7	M	72	Prostate	Adenocarcinoma	2	II	3	2+3	T2N0M0	Malignant
A8	8	M	76	Prostate	Adenocarcinoma	2	II	3	2+3	T2N0M0	Malignant
A9	9	M	71	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
A10	10	M	65	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
B1	11	M	64	Prostate	Adenocarcinoma	2	I	3	3+3	T1N0M0	Malignant
B2	12	M	71	Prostate	Adenocarcinoma	3	II	4	5+4	T2N0M0	Malignant
B3	13	M	71	Prostate	Adenocarcinoma	2	I	3	3+3	T1N0M0	Malignant
B4	14	M	72	Prostate	Adenocarcinoma (smooth muscle)	–	II	–	–	T2N0M0	Malignant
B5	15	M	70	Prostate	Adenocarcinoma	3	II	5	5+5	T2N0M0	Malignant
B6	16	M	73	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
B7	17	M	70	Prostate	Adenocarcinoma	2	IV	3	4+3	T2N1M1c	Malignant
B8	18	M	65	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
B9	19	M	75	Prostate	Adenocarcinoma	2	IV	3	4+3	T4N1M1	Malignant
B10	20	M	76	Prostate	Adenocarcinoma (prostate tissue)	–	II	–	–	T2aN0M0	Malignant
C1	21	M	64	Prostate	Adenocarcinoma	2	IV	3	4+3	T3N0M1	Malignant
C2	22	M	74	Prostate	Adenocarcinoma	2–3	IV	4	5+3	T4N1M1c	Malignant
C3	23	M	62	Prostate	Adenocarcinoma	2	IV	3	4+3	T3N1M1b	Malignant
C4	24	M	64	Prostate	Adenocarcinoma	2–3	II	4	5+3	T2aN0M0	Malignant
C5	25	M	58	Prostate	Adenocarcinoma	2	II	4	4+3	T2N0M0	Malignant
C6	26	M	56	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
C7	27	M	62	Prostate	Adenocarcinoma	2	II	3	3+3	T2N0M0	Malignant
C8	28	M	73	Prostate	Adenocarcinoma	2	II	3	3+3	T2N0M0	Malignant
C9	29	M	71	Prostate	Adenocarcinoma	2	II	4	4+3	T2N0M0	Malignant
C10	30	M	64	Prostate	Adenocarcinoma	2–3	II	4	3+5	T2N0M0	Malignant
D1	31	M	70	Prostate	Adenocarcinoma (sparse)	–	III	–	–	T3N0M0	Malignant
D2	32	M	73	Prostate	Adenocarcinoma (prostate tissue)	–	II	–	–	T2N0M0	Malignant
D3	33	M	70	Prostate	Adenocarcinoma	2	IV	3	4+3	T3N1M0	Malignant
D4	34	M	72	Prostate	Adenocarcinoma	3	IV	4	5+4	T4N0M0	Malignant
D5	35	M	64	Prostate	Adenocarcinoma	3	IV	4	5+4	T3N0M1a	Malignant
D6	36	M	80	Prostate	Adenocarcinoma	2	IV	3	4+3	T4N1M1c	Malignant
D7	37	M	69	Prostate	Adenocarcinoma	2	III	3	4+3	T3bN0M0	Malignant
D8	38	M	73	Prostate	Adenocarcinoma	3	III	4	5+4	T3N1M1	Malignant
D9	39	M	73	Prostate	Adenocarcinoma	2–3	IV	4	5+3	T3N1M1b	Malignant
D10	40	M	65	Prostate	Adenocarcinoma	2–3	IV	4	3+5	T2N1M1	Malignant
E1	41	M	82	Prostate	Adenocarcinoma	2	IV	3	4+3	T3N2M1	Malignant
E2	42	M	51	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
E3	43	M	72	Prostate	Adenocarcinoma	2–3	III	4	5+3	T3N0M0	Malignant
E4	44	M	66	Prostate	Adenocarcinoma	2	III	3	4+3	T3aN0M0	Malignant
E5	45	M	20	Prostate	Adenocarcinoma	2	III	3	3+3	T3N0M0	Malignant
E6	46	M	61	Prostate	Adenocarcinoma	3	IV	4	5+4	T3N1M0	Malignant
E7	47	M	64	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
E8	48	M	60	Prostate	Adenocarcinoma	2	IV	3	4+3	T3N1M0	Malignant
E9	49	M	68	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
E10	50	M	82	Prostate	Adenocarcinoma	3	II	5	5+5	T2N0M0	Malignant
F1	51	M	78	Prostate	Adenocarcinoma	3	IV	4	5+4	T3N2M1	Malignant
F2	52	M	87	Prostate	Adenocarcinoma	3	II	5	5+5	T2N0M0	Malignant
F3	53	M	81	Prostate	Adenocarcinoma	3	III	4	5+4	T3aN0M0	Malignant
F4	54	M	76	Prostate	Adenocarcinoma	3	IV	5	5+5	T3N1M1b	Malignant
F5	55	M	73	Prostate	Adenocarcinoma	3	IV	4	5+4	T4N1M1c	Malignant
F6	56	M	78	Prostate	Adenocarcinoma	3	IV	5	5+5	T4N1M1	Malignant
F7	57	M	40	Prostate	Adenocarcinoma	3	IV	4	5+4	T2N1M1b	Malignant
F8	58	M	69	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
F9	59	M	62	Prostate	Adenocarcinoma	3	II	5	5+5	T2N0M0	Malignant
F10	60	M	67	Prostate	Adenocarcinoma	3	II	5	5+5	T2N0M0	Malignant
G1	61	M	64	Prostate	Adenocarcinoma	3	II	5	5+5	T2N0M0	Malignant
G2	62	M	77	Prostate	Adenocarcinoma	2	II	3	4+3	T2N0M0	Malignant
G3	63	M	26	Prostate	Adenocarcinoma (prostate tissue)	–	II	–	–	T2N0M0	Malignant
G4	64	M	69	Prostate	Adenocarcinoma	3	IV	5	5+5	T4N0M0	Malignant
G5	65	M	73	Prostate	Adenocarcinoma	2	III	3	4+3	T3N0M0	Malignant
G6	66	M	82	Prostate	Adenocarcinoma	2–3	II	4	5+3	T2N0M0	Malignant
G7	67	M	63	Prostate	Adenocarcinoma	2–3	IV	4	5+3	T2N1M1b	Malignant
G8	68	M	55	Prostate	Adenocarcinoma	3	II	4	5+4	T2N0M0	Malignant
G9	69	M	75	Prostate	Adenocarcinoma with necrosis	3	III	4	5+4	T3N0M0	Malignant
G10	70	M	72	Prostate	Adenocarcinoma	3	IV	4	5+4	T2N0M1	Malignant
H1	71	M	60	Prostate	Adenocarcinoma (sparse)	–	II	–	–	T2N0M0	Malignant
H2	72	M	72	Prostate	Leiomyosarcoma	–	II	–	–	T2N0M0 G2	Malignant
H3	73	M	67	Prostate	Pleomorphic leiomyosarcoma	–	IIIB	–	–	T2N0M0 G3	Malignant
H4	74	M	27	Prostate	Hyperplasia	–	–	–	–	–	Hyperplasia
H5	75	M	35	Prostate	Cancer adjacent normal prostate tissue	–	–	–	–	–	NAT
H6	76	M	21	Prostate	Cancer adjacent normal prostate tissue	–	–	–	–	–	NAT
H7	77	M	45	Prostate	Normal prostate tissue	–	–	–	–	–	Normal
H8	78	M	37	Prostate	Normal prostate tissue	–	–	–	–	–	Normal
H9	79	M	33	Prostate	Normal prostate tissue	–	–	–	–	–	Normal
H10	80	M	43	Prostate	Normal prostate tissue	–	–	–	–	–	Normal
–	–	M	42	Adrenal gland	Pheochromocytoma (tissue marker)	–					Malignant

† For precise diagnosis, refer to pathology description.

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array:

Paraffin Embedded Tissue Array Types [view all]

Human

Cell Arrays (2)

Mouse (16)

Rat (9)

Monkey (5)

Frozen Tissue Arrays (54)

PR803a

*Tissue Microarray Slide Types:

Microarray Panel Display

Specification Sheet

TNM grading: